2013
DOI: 10.1038/ng.2646
|View full text |Cite
|
Sign up to set email alerts
|

Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

24
572
1
13

Year Published

2015
2015
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 606 publications
(610 citation statements)
references
References 41 publications
24
572
1
13
Order By: Relevance
“…1A). Two missense mutations of Arg1872 were described in seven patients1, 3, 11, 18 and we describe a third substitution in two patients, making this the most frequently mutated residue. The CpG dinucleotides in the codons for Arg1617 and Arg1872 are mutational hotspots (Fig.…”
Section: Introductionmentioning
confidence: 69%
“…1A). Two missense mutations of Arg1872 were described in seven patients1, 3, 11, 18 and we describe a third substitution in two patients, making this the most frequently mutated residue. The CpG dinucleotides in the codons for Arg1617 and Arg1872 are mutational hotspots (Fig.…”
Section: Introductionmentioning
confidence: 69%
“…Supplementary Table I summarizes the available clinical data on the 26 individuals who have been reported to date with presumed causative mutations in SYNGAP1 or deletions or translocations involving this gene [Hamdan et al, 2009, 2011a, b; Krepischi et al, 2010; Pinto et al, 2010; Vissers et al, 2010; Cook, 2011; Klitten et al, 2011; Zollino et al, 2011; Clement et al, 2012; de Ligt et al, 2012; Rauch et al, 2012; Berryer et al, 2013; Carvill et al, 2013; Writzl and Knegt, 2013; Dyment et al, 2014; O'Roak et al, 2014; Redin et al, 2014]. De novo mutations in this gene are undoubtedly a significant cause of intellectual disability, accounting for 0.62% of all the patients in the DDD Study [Wright et al, 2014] and major contributors to other cohorts that have been studied (Supplementary Table II).…”
Section: Discussionmentioning
confidence: 99%
“…Heterozygous, de novo loss‐of‐function mutations in SYNGAP1 have been described in 26 individuals to date [Hamdan et al, 2009, 2011a, b; Krepischi et al, 2010; Pinto et al, 2010; Vissers et al, 2010; Zollino et al, 2011; de Ligt et al, 2012; Rauch et al, 2012; Berryer et al, 2013; Carvill et al, 2013; Writzl and Knegt, 2013; Redin et al, 2014]. SYNGAP1 encodes Ras/Rap GTPase‐activating protein SynGAP, which is a major component of the post‐synaptic density that regulates synaptic plasticity and ERK/MAPK signaling probably via N‐methyl‐d‐aspartate (NMDA) receptor activation [Komiyama et al, 2002; Muhia et al, 2010].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…This means that the definitive etiology is known, although factors influencing phenotypic variability are usually not yet understood, such as modifier genes or the influence of environmental factors. Many new etiological diagnoses are emerging such as CHD2 encephalopathy, KCNQ2 encephalopathy, and STXBP1 encephalopathy, to name a few 6, 7, 8, 9. One of the best‐known examples is an individual with Dravet syndrome, who has a known mutation of the sodium channel gene SCN1A 10…”
Section: Proposal For a Framework For Epilepsy Classification And Diamentioning
confidence: 99%